PR: Applied DNA secures grant from National Grid partnered with the New York State MEP to support manufacture of COVID-19 diagnostic kits and vaccine candidates

Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company,” “our”) announced today it secured a $40,000 economic development grant from National Grid to support the Company’s efforts associated with the manufacture of COVID-19-related therapeutics and diagnostics programs. National Grid is one of the largest investor-owned energy companies in the U.S. and serves more than 20 million customers throughout New York, Massachusetts, and Rhode Island.

National Grid’s grants focus on supporting businesses that make critical products for healthcare providers, governments, and other community organizations to navigate through the COVID-19 pandemic. National Grid collaborates with New York State Manufacturing Extension Partnership centers to evaluate business need and offer funding of up to $40,000 to reimburse recipients for costs associated with the transition, upgrade, and implementation of lean manufacturing principles at their existing facilities in the fight against COVID-19.

“We are grateful for National Grid and New York State’s focus on the Long Island community in this time of crisis. This funding will be used to increase our capacity to deliver quantities of our RT-PCR test for COVID-19 that was recently approved under Emergency Use Authorization by the FDA for clinical use, and to support the pathway toward human trials of selected vaccine candidates we have jointly developed with Takis Biotech” said Dr. James Hayward, president and CEO at Applied DNA. “Our orchestrated approach to our development programs aimed at vanquishing COVID-19 we believe is unique, and we share a deep motivation as fellow Long Islanders to support local communities and governments, that are working tirelessly to manage within the pandemic.”

About Applied DNA Sciences, Inc.

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, diagnostics and pre-clinical nucleic acid-based therapeutic drug candidates.

     Want our news sent directly to your inbox?

Yes please 2

Home  |  About us  |  Contact us  |  Advertise  |  Links  |  Partners  |  Privacy Policy  |   |  RSS feed   |  back to top